Skip to main content
. 2022 Aug 31;71(5):667–675. doi: 10.33549/physiolres.934914

Fig. 1.

Fig. 1

VSMC viabilities and migratory ability with Ang II treatment. (A) CCK-8 assay was applied for evaluating VSMC viabilities with Ang II treatment (0, 0.05 and 0.1 μM). (B, C) Transwell was used for detecting VSMC migration with Ang II treatment. (D, E) Western blot was applied to examine MCP-1 and MMP-9 protein expressions after Ang II treatment. ** P<0.05.